Novo Nordisk Commits €432 Million to Expand Athlone Oral-Drug Production
Novo Nordisk will invest 432 million euros ($506.43 million) to enlarge its Athlone, Ireland manufacturing site. The project is intended to boost production of oral products, including oral versions of GLP-1 medicines such as Wegovy and Ozempic, and to strengthen the company’s ability to serve demand outside the United States. Construction is under…